Conceptos Categóricos

Crónicas de autores

Ignacio García Doval *

Autor invitado por SIIC

Análisis del Registro Español de Acontecimientos Adversos de Terapias Biológicas en Reumatología (BIOBADASER)

AUMENTO DE LA GRAVEDAD, PERO NO CLARAMENTE DE LA FRECUENCIA, DE INFECCIONES POR VIRUS HERPES ZOSTER EN PACIENTES CON ANTI-TNF

La tasa de infecciones o reinfecciones por el virus varicela zóster en los pacientes tratados con anti-TNF puede o no estar aumentada claramente, pero la gravedad de las infecciones puede incrementarse; sin embargo, el número total de casos es bajo para justificar una vacuna que no tiene una cobertura perfecta fuera de los calendarios de vacunación.

*Ignacio García Doval
describe para SIIC los aspectos relevantes de su trabajo
INCIDENCE AND RISK OF HOSPITALISATION DUE TO SHINGLES AND CHICKENPOX IN PATIENTS WITH RHEUMATIC DISEASES TREATED WITH TNF ANTAGONISTS
Annals of the Rheumatic Diseases,
69(10):1751-1755 Oct, 2010

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Complexo Hospitalario de Pontevedra, Madrid, España
Imprimir nota
Referencias bibliográficas
Wung PK, Holbrook JT, Hoffman GS, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 118:1416, 2005.
Opstelten W, Mauritz JW, de Wit NJ, et al. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 19:471-5, 2002.
Gómez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57:756-61, 2007.
Ito M, Nakano T, Kamiya T, et al. Effects of tumor necrosis factor alpha on replication of varicella-zoster virus. Antiviral Res 15:183-92, 1991.
Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57:1431-8, 2007.
Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 45:1370-5, 2006.
Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301:737-44, 2009.
Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766-72, 2005.
Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122-7, 2003.
MedDRA Maintenance and Support Services Organization. http://www.meddramsso.org. Accessed 26 Mar 2010.
Ministerio de Sanidad y Consumo. Encuesta Nacional de Salud 2003. http://www.msc.es/estadEstudios/estadisticas/encuestaNacional/home.htm. Accessed 27 Oct 2008.
Instituto Nacional de Estadística (INE). http://www.ine.es. Accessed 28 Nov 2008.
Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66:880-5, 2007.
Carmona L, Hernández-García C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30:1436-9, 2003.
Spanish Society of Rheumatology. BIOBADASER: Spanish Registry for Adverse Events of Biological Therapies in Rheumatic Diseases. http://biobadaser.ser.es/biobadaser/eng/index.html. Accessed 26 Mar 2010.
Descalzo MA, Biobadaser Scientific Committee (CC), Biobadaser Study Group (SG). Spanish registry for adverse events of biological therapies in rheumatic diseases (BIOBADASER): State Report on January 26th 2006. Reumatol Clin 3:4-20, 2007.
Terris DD, Litaker DG, Koroukian SM. Health state information derived from secondary databases is affected by multiple sources of bias. J Clin Epidemiol 60:734-41, 2007.
Calle JE, Saturno PJ, Parra P, et al. Quality of the information contained in the minimum basic data set: results from an evaluation in eight hospitals. Eur J Epidemiol 16:1073-80, 2000.
Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am 10:571-81, 1996.
Nilsson A, Ortqvist A. Severe varicella pneumonia in adults in Stockholm County 1980-1989. Scand J Infect Dis 28:121-3, 1996.
De Melker H, Berbers G, Hahné S, et al. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 24:3946-52, 2006.
Torigo S, Ihara T, Kamiya H. IL-12, IFN-gamma, and TNF-alpha released from mononuclear cells inhibit the spread of varicella-zoster virus at an early stage of varicella. Microbiol Immunol 44:1027-31, 2000.
Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56(RR-4):1-40, 2007.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271-84, 2005.
Peña-Rey I, Martínez de Aragón MV, Villaverde Hueso A, et al. Epidemiology of varicella in Spain pre- and post-vaccination periods. Rev Esp Salud Publica 83:711-24, 2009.


ua40317
-->